Chemo-irradiation induced oxidative damage to vascular endothelium may contribute to pulmonary complications of hematopoietic stem cell transplantation (HSCT). We measured antioxidants, markers of oxidative stress and plasma antioxidant capacity in plasma or serum from 24 subjects at day 7 before HSCT and 20 control subjects. The plasma concentration of extracellular glutathione peroxidase (GPX-3) was significantly reduced in the HSCT subjects compared with controls (HSCT: 98742 lg/ml, control: 169756 lg/ml, Po0.0001). The concentration of c-tocopherol was significantly higher in the HSCT subjects compared with controls (HSCT: 2077103 lg/dl; Control: 98752 lg/dl; P ¼ 0.0002). The plasma concentrations of protein carbonyl, nitrotyrosine, malondialdehyde, a-tocopherol, vitamin A, homocysteine, cysteine and cysteinylglycine did not differ between HSCT and control subjects. Plasma from HSCT subjects was as effective as control plasma in quenching menadione-induced intracellular reactive oxygen species production in human microvascular endothelial cells. In summary, subjects before HSCT have significantly reduced plasma concentrations of GPX-3, elevated plasma c-tocopherol yet retains the ability to quench an acute oxidative stress. These changes may play a role in chronic oxidative stress in the HSCT population.
Introduction
Pulmonary complications cause significant morbidity and mortality in subjects undergoing hematopoietic stem cell transplantation (HSCT) . 1 The precise pathophysiology of HSCT-related pulmonary complications is not fully understood but animal data suggest that the process of HSCT is associated with an imbalance in the production and breakdown of reactive oxygen species (ROS) including superoxide anion, hydrogen peroxides and peroxynitrites. 2, 3 The intensive chemotherapy and radiation used for marrow ablation and the subsequent influx of donor neutrophils during stem cell engraftment are considered important triggers of excessive ROS generation both in the lung and in other essential organs of subjects undergoing HSCT. 2 In addition, iron overload from prior blood transfusions has been demonstrated in subjects undergoing HSCT. 4 Iron overload may contribute to oxidant-induced damage to tissues by acting as a free radical catalyst of either the Fenton reaction or the Haber-Weiss reaction. 4, 5 Thus, an ongoing self-perpetuating chronic oxidative stress with cellular and organ senescence 6, 7 may be important in some of the late pulmonary complications of HSCT.
An extensive system of enzymatic and non-enzymatic antioxidants regulates ROS production in mammalian cells. Small studies have suggested that the process of HSCT depletes certain components of the non-enzymatic antioxidants in plasma such as vitamin E, 8 plasma retinol and g-tocopherol. 9 The enzymatic antioxidant enzymes include the glutathione peroxidases (GPXs), superoxide dismutase and catalase. 10 We have developed the hypothesis that some of the complications seen post-HSCT may begin in the pre-HSCT period. 11 In this study we have compared the plasma concentration of extracellular GPX-3, other non-enzymatic components of the circulating antioxidant system and markers of oxidative stress in subjects at day 7 before HSCT with a group of normal controls. In addition, we have compared the ability of plasma from HSCT subjects to quench ROS formation in cultured human microvascular endothelial cells with that of plasma from a control population.
Materials and methods

Study populations
There were two populations in this study: a sequential cohort of 24 subjects undergoing HSCT at Tufts-New England Medical Center (T-NEMC) and 20 healthy nonsmoking controls. Exclusion criteria for both groups included age either less than 18 years or over 65 years and pregnancy. The healthy control population was recruited from hospital employees within T-NEMC by advertising. The entire study was approved by the Human Investigation Review Board (IRB) at T-NEMC and all subjects gave written informed consent.
Demographic, clinical and diagnostic data
The following data were collected from the paper and electronic medical records of each patient: ethnicity, age, sex, underlying hematological diagnosis, date underlying hematological diagnosis was made, date and type of current and any prior HSCT, amount of chemotherapy received before transplant, days elapsed from date of initial diagnosis to HSCT, days elapsed from last cycle of chemotherapy to HSCT and survival to day 100 following HSCT. The total load of chemotherapy received by subjects before undergoing HSCT was calculated from outpatient medical and pharmacy records and expressed in units of chemotherapy as described previously.
11
Diffusing capacity for carbon monoxide Diffusing capacity for carbon monoxide (Dlco) was measured using the single-breath technique as reported previously 11 and expressed as ml/mmHg/min. The values obtained were related to standard normal values. 12 
Blood samples
Informed consent was obtained from each subject and 25 ml blood (plasma 10 ml, serum 10 ml and whole blood 5 ml) was obtained either by direct venepuncture or through a central line (after clearing the line). When possible the research blood samples were obtained from HSCT subjects at the same time as a clinically indicated blood draw in order to avoid an additional venepuncture. The research blood samples were obtained in the HSCT subjects at day À7, 1 day before the subjects undergoing conditioning treatment before transplant. All plasma and serum samples were centrifuged, stored at À801C, deidentified and given new research numbers in accordance with Federal Health Insurance Portability and Accountability Act (HIPAA) guidelines.
GPX 3 and nitrotyrosine
The concentrations of GPX-3 and nitrotyrosine in plasma, cell lysates and conditioned medium were measured using enzyme-linked immunosorbent assay (ELISA) (OxisResearch, Portland, OR, USA). Each sample was run in duplicate and each experiment was repeated at least twice. Sample concentration was determined from the standard curve according to the supplied instructions.
Retinol and a-and g-tocopherol Plasma was deproteinized with ethanol, extracted in hexane, dried under nitrogen and reconstituted in methanol/ethyl ether (3/1:v/v). Samples were injected onto a J 0 sphere Output Delivery System reverse-phase column (YMC) and analyzed by high-pressure liquid chromatography (HPLC), (Millennium System, Golden Valley, MN, Waters Associates) with UV detection (Waters 490, Golden Valley, MN) at 292 nm for vitamin E and 540 nm for vitamin A according to Bieri et al. 13 The concentrations of both the retinol and a-and g-tocopherol standards (Sigma, St Louis, MO) were verified spectrophotometrically.
Plasma markers of oxidative damage protein and lipid Protein carbonyls in plasma were determined according to Levine. 14 Final protein carbonyl concentrations were adjusted for sample protein concentration. Bound malondialdehyde (MDA) in plasma was released from protein with 10 N NaOH, reacted with thiobarbituric acid (TBA) at 951C for 30 min, and the MDA-TBA complex analyzed by reverse-phase HPLC (Hewlett Packard 1100, Palo Alto, CA) with fluorescence detection as described. [15] [16] [17] Plasma total homocysteine, cysteine and cysteinylglycine Plasma concentrations of total homocysteine, cysteine and cysteinylglycine were determined with reverse-phase HPLC using a C18 column on a Waters HPLC instrument equipped with a WISP automatic injector and attached to a fluorimeter (Applied Sciences Inc., Dayton, OH). as described by Araki and Sako. 18 The inter and intra assay variabilities were less than 5%.
Cell culture
Human pulmonary artery microvascular endothelial cells (HMVEC) were obtained from Cambrex (San Diego, CA, USA), and were grown in special media endothelial growth medium (EGM-2) provided by the company. Cells were grown in a tissue culture incubator maintained at 5% CO 2 and 371C. Cells were then seeded onto 35 mm dishes and grown in Rosewell Park Memorial Institute media (RPMI) (5%, with antibiotics). HMVECs exhibit typical endothelial cobblestone morphology. Cells were growth arrested for 24 h in serum-free RPMI before exposure to plasma.
ROS
We used a previously described method that utilized lucigenin-enhanced chemiluminescence to measure intracellular ROS (in this case superoxide anion, O 2 À ) production. 19 This assay is based on the reaction between reduced lucigenin and O 2 À resulting in the emission of light. 20 HMVECs were grown to 90-100% confluency on 35 mm dishes and then serum-starved for 24 h. The medium was replaced with 1 ml of serum-free RPMI 1640 medium containing 1 mM lucigenin without phenol red. For the experiments using plasma samples (either pooled or individual) HMVEC were pretreated for 30 min with 5% plasma with or without 2.75 mM menadione. Chemiluminescence was recorded using a TD -20/20 luminometer (Turner Designs, Sunnyvale, CA, USA) as described previously. 19 Specificity of the reaction for O 2 was demonstrated by the almost complete inhibition of the signal by preincubating for 30 min with Tiron (1 mM), an intracellular O 2 scavenger. The average of seven readings taken at 1 min intervals was calculated for each sample and each sample was run in duplicate. Each experiment was repeated at least three times.
Vitamin and supplement use. A follow-up study to determine vitamin and supplement use by study participants at the time of the research blood draw was performed. A short questionnaire was approved by the IRB and mailed to all study participants at their last known address. The questionnaire was sensitive to the fact that 50% of the HSCT subjects were known to have died after the study was completed and asked study survivors to consider responding for the deceased participant.
Statistical analysis
Statistical comparisons were performed using the Student's t-test for unpaired samples and the w 2 test for categorical variables. Statistical significance was determined at Po0.05.
Results
Demographic data
Demographic and clinical data for the HSCT and control populations are shown in Table 1 . The HSCT population was significantly older than the control population. The proportion of females between the two groups was not significantly different. Nineteen subjects were known to have received chemotherapy before HSCT, three subjects did not receive any treatment before HSCT and in two subjects the data were not available. Of those receiving chemotherapy before HSCT, 50% were treated at the referring facility before HSCT.
GPX-3 is reduced in HSCT subjects compared with controls
The mean concentration of plasma GPX-3 was significantly reduced in the HSCT group as compared to the control group (Po0.0001) ( Figure 1 ). No significant correlation was observed between the plasma concentration of GPX-3 and either the chemotherapy burden received before HSCT or the time elapsed from diagnosis to HSCT.
In a subgroup of HSCT subjects (n ¼ 9) we were able to obtain additional plasma samples at day 100720 following HSCT. There was no significant difference seen between the concentration of plasma GPX-3 concentrations measured before and after HSCT (HSCT pre-transplant: 787 52 mg/ml; HSCT day 100720: 71724 mg/ml, P ¼ 0.714). The concentration of GPX-3 in the post-HSCT period remained significantly lower than the control values. Table 1 Demographics and clinical data on HSCT and control subjects Twenty-two (92%) of the 24 HSCT subjects survived to day 100 post transplant. Both of the subjects who died had GPX-3 concentrations below 100 mg/ml but the small numbers of subjects in the cohort preclude more detailed survival analysis. There was no significant correlation observed between the plasma concentration of GPX-3 and the chemotherapy burden received before HSCT (Pearson's correlation coefficient: À0.012, P ¼ 0.96). There was no significant correlation noted between plasma GPX-3 concentration and time elapsed from diagnosis to HSCT (r ¼ 0.097) in those undergoing HSCT.
Measurements of non-enzymatic antioxidants
The concentration of g-tocopherol was significantly higher in the HSCT subjects compared with the control subjects (HSCT: 2077103 mg/dl; Control: 98752 mg/dl; P ¼ 0.0002) (Figure 2 ). There was no significant difference in the plasma concentration of vitamin A and a-tocopherol between the two groups. (Vitamin A: HSCT: 65725 mg/dl, control 60721 mg/dl, P ¼ 0.46. a-tocopherol: HSCT: 13067468 mg/ dl, control: 11167524 mg/dl, P ¼ 0.23.)
Vitamin or mineral supplement use. We were able to contact 10 (50%) of the controls and of them 30% reported using vitamin supplements at the time of the blood draw. Of the 24 HSCT subjects and their survivors (50% of HSCT subjects had died after the study was started) only four (16%) returned the questionnaire. Two (50%) of the respondents reported vitamin use by the HSCT subject at the time of the blood draw. The remaining 20 HSCT subjects or their survivors did not return the questionnaire, had moved to an unknown address or did not wish to answer the questions.
Measurements of homocysteine, cysteine and cysteinylglycine
The plasma concentrations of homocysteine (HSCT: 12.0573.7, control: 10.473.9, P ¼ 0.33), cysteine (HSCT: 328751, control: 284752, P ¼ 0.07) or cysteinylglycine (HSCT: 4037153, control: 3257101, P ¼ 0.194) were not significantly different between controls (n ¼ 10) and HSCT (n ¼ 10) subjects.
Circulating markers of oxidative stress Samples were tested for evidence of oxidative damage to protein, lipid and nucleic acid. The concentration of protein carbonyl in plasma was compared between HSCT subjects and controls. There was no significant difference in the plasma concentration of protein carbonyl between the two groups (HSCT: 2.370.99 nmol/mg protein; control 3.0371.7 nmol/mg protein, P ¼ 0.157). The plasma concentration of MDA was measured as a marker of lipid peroxidation. There was no significant difference between the HSCT and control groups (HSCT: 0.9770.34 mmol; control: 0.8670.28 mmol, P ¼ 0.27). Nitrotyrosine was measured using a commercially available ELISA kit. These experiments showed no difference between HSCT and controls (HSCT: 957149 nM, Control: 2017262 nM; P ¼ 0.128).
Effect of plasma on ROS release from HMVEC
The purpose of this experiment was to compare the effect of HSCT plasma with 'low' GPX-3 (concentration below the 50th percentile, GPX-3 o100 mg/ml) (n ¼ 6) with that of control plasma with 'normal' concentrations of GPX-3 (concentration above the 50th percentile, GPX-3 4175 mg/ ml) (n ¼ 6) on the intracellular production of O 2 À in HMVEC. We compared the effect of plasma on either baseline ROS production or on ROS production in response to menadione, 21 which induces ROS in a predictable manner in cultured endothelial cells. Menadione was selected in an attempt to simulate the oxidative stress effect of HSCT on the vascular endothelium.
The results of a representative experiment of multiple experiments are shown in Figure 3 . Similar data were obtained when pooled samples from the two groups of plasma samples (HSCT plasma with 'low' GPX-3 (n ¼ 5) and control plasma with normal GPX-3 (n ¼ 5)) were used. Menadione reliably increased intracellular ROS production in HMVEC compared with baseline and therefore was used as a positive control. The increase in ROS in HMVEC in response to menadione was reliably inhibited by 490% with Tiron 1 mM (data not shown) as previously reported. 19 Pretreating HMVEC with either HSCT or control plasma significantly reduced the baseline production of ROS but there was no significant difference between the effect of either HSCT or control plasma on baseline ROS produc- 
Po0.05 compared with baseline.
tion. Pretreating HMVEC with either HSCT or control plasma also inhibited the increase in ROS seen with menadione. There was no difference seen in the magnitude of the quenching effect of either HSCT or control plasma samples on the menadione-induced ROS production.
Thus, plasma from HSCT subjects with low GPX-3 and controls with normal GPX-3 did not differ in their ability to quench baseline and menadione-induced ROS production in HMVEC.
Discussion
In this study we have demonstrated changes in the circulating antioxidant system in the plasma of subjects just before undergoing HSCT. The two major novel findings of this study are a reduction in the plasma concentration of GPX-3 and an elevation in the plasma concentration of g-tocopherol in subjects just before HSCT compared with controls. There is evidence from both human studies and animal models that subjects undergoing HSCT are exposed to oxidative stress but there have been no studies to date on GPX-3 in the HSCT population. A number of studies have shown that the process of HSCT depletes non-enzymatic antioxidants such as plasma thiol antioxidants, vitamin E, uric acid and plasma retinol. 8, 9, 22 The use of combination chemotherapy has also been shown to increase free radical production in subjects with cancer. 23 Recent data suggest that both acute and chronic iron overload may occur in subjects undergoing HSCT and as a result free iron-generated ROS may contribute to cell and tissue damage in the post transplant period. 5, [24] [25] [26] The role of iron-generated ROS and oxidative stress in complications of HSCT has been recently reviewed. 4 Using an ELISA-based assay we have demonstrated a significant reduction in the plasma concentration of GPX-3 protein in subjects just before HSCT compared with a control population. The four genetically distinct GPX enzymes are considered the principal antioxidant enzymes in mammalian cells 27, 28 and they reduce hydrogen peroxide and phospholipid hydroperoxides using reduced glutathione as a co-factor. 10 The GPX-1 isoform of GPX is located predominantly in the intracellular compartment and reduced concentrations of this isoform have been reported to be an independent risk factor for cardiovascular events. 29 GPX-2 provides antioxidant protection to the gastrointestinal mucosal surface and GPX-4 is located on cell membranes and in the cytosol. 10 GPX-3 is a genetically distinct member of the GPX family of enzymes and is the only extracellular isoform that circulates in plasma. Analysis of the GPX-3 gene shows it to be located on chromosome 5q32-q33 and containing five exons. 30 The sequence of GPX-3 is highly conserved among mammalian species and the enzyme is therefore considered essential for mammalian survival in an oxygen-rich environment. 31 Recent genetic studies have indicated that hypoxia may be a key regulator of transcription of the GPX-3 gene through a HIF-1-dependent mechanism. 32 The majority of plasma GPX-3 is synthesized in the renal proximal tubular cells and the parietal epithelial cells of Bowman's capsule. 33 Small amounts of GPX-3 are also synthesized in the lung, heart, intestine and placenta. 34, 35 GPX-3 is released into extracellular fluid following synthesis, comprises almost 60% of the total GPX activity found in broncho-alveolar fluid 36 and as a result is considered an important component of pulmonary antioxidant defenses. The assembled GPX-3 molecule is a glycosylated tetramer of 23-kDa subunits and is a major scavenger of ROS produced during normal metabolic activity or following oxidative stress. 32 Along with other antioxidants, GPX-3 is thought to protect the vascular endothelium from injury owing to low levels of oxidized lipids found in plasma. 31 The in vivo regulation of plasma GPX-3 concentrations in humans and the response of the enzyme to either acute or chronic oxidative stress are not well understood. A previous study of plasma GPX-3 in healthy adults reported higher GPX-3 concentrations and activities in females compared with males. 37 In our study the distribution of females in the two groups was not significantly different. However, the age of the HSCT group was on average 10 years older than the control group. An increase in oxidative events has been described with increasing age, 38 however, there are no reports of significant differences in the plasma GPX-3 concentration in these age groups. The storage of blood has been shown to deplete antioxidants from red blood cells and plasma, 39 however, this effect would be expected to affect all samples equally. There are a number of other possible causes for a reduction in plasma GPX-3 concentration such as genetic polymorphisms in the GPX-3 gene, altered post-translational regulation of the GPX-3 protein, increased breakdown of the GPX-3 protein and a damaging effect of cumulative cycles of chemotherapy. The lack of any significant correlation between the plasma concentration of GPX-3 and the calculated burden of chemotherapy received in the HSCT subjects, 11 along with the median time elapsed from the last cycle of chemotherapy to HSCT of 64 days make it unlikely that the burden or timing of prior chemotherapy contribute to the reduction in GPX-3 concentration in the HSCT subjects. We are currently comparing the sequences of the GPX-3 gene in those HSCT subjects with low GPX-3 concentrations with those of normal subjects to determine if nucleotide changes in the GPX-3 gene are associated with lower plasma enzyme concentrations.
A reduction in the plasma concentration of GPX-3 may increase the likelihood of oxidative damage to the vascular endothelium from ROS as circulating GPX-3 appears to be a rich source of enzymatic antioxidants for the lung. 35 Using a translational approach we compared the ability of HSCT plasma with the lowest concentrations of GPX-3 (o100 mg/ml) and control plasma with normal-to-high GPX-3 (4175 mg/ml) to modulate basal and menadioneinduced ROS production in cultured HMVEC. These studies were an attempt to simulate in vitro the in vivo effects of chemo-irradiation on vascular endothelium. The results indicated that HSCT plasma appears to be as effective as control plasma in quenching basal intracellular ROS production in HMVEC. Plasma from either HSCT with low GPX-3 or controls with normal to high GPX-3 appeared to have no significant effect on menadioneinduced ROS production in HMVEC. These initial translational data obtained in HMVEC suggest that the lower concentration of GPX-3 in HSCT subjects did not appear to compromise the plasma antioxidant capacities. Additional translational experiments will help determine the effect of plasma on extracellular ROS production. We interpret this as a reflection of the redundancy of the plasma antioxidant system with loss of one component being compensated for by others. Whether or not the lower plasma concentrations of GPX-3 play a role in morbidity beyond day 100 is not clear at this time. Studies performed with other GPX isoforms (GPX-1) support the general concept that a reduction in circulating antioxidant enzymes may increase endothelial dysfunction in response to an increase in ROS. 40 For example, animals homozygous for GPX-1 deficiency have been shown to have enhanced susceptibility to oxidative injury such as myocardial perfusion injury. 41 In animals with targeted gene disruption of the GPX-1 gene, endothelial function was impaired. 42 Therefore, it is conceivable that subjects with a reduction in the plasma concentrations of circulating GPX-3 undergoing HSCT may be at increased risk of organ damage beyond day 100 following transplant. In the small cohort of subjects in this study we were unable to demonstrate an increased incidence of organ damage in those with concentrations of GPX-3 below 100 mg/ml (data not shown). This study was not powered to determine if low plasma concentrations of GPX-3 were a risk factor for organ damage.
Hyperhomocysteinemia has been shown to be a risk factor for endothelial dysfunction possibly through the oxidative inactivation of endothelium derived nitric oxide. 43, 44 The GPX system, in particular the cellular GPX-1 isoform, appears to provide protection against peroxide-induced endothelial dysfunction in animals with hyperhomocysteinemia. 40 In vitro studies have demonstrated an inhibitory effect of homocysteine on plasma peroxidase activity raising the possibility that low plasma GPX activity may be a risk factor for cardiovascular disease. 31 We were unable to demonstrate any difference in plasma homocysteine, cysteine and cysteinylglycine concentrations between HSCT subjects and controls in the pre-HSCT period. It is not known if hyperhomocysteinemia occurs in the post-HSCT period and if it plays any role in post-HSCT vascular events such as thromboembolic disease.
The second major finding of this study was a significant increase in plasma g-tocopherol concentration in the HSCT subjects compared with controls. Vitamin E occurs in nature in at least eight forms, four tocopherols and four tocotrienols. 45 All forms act as potent membrane soluble antioxidants and by donating phenolic hydrogen's to lipid radicals protect membrane polyunsaturated fat from lipid peroxidation. 45 g-Tocopherol makes up about 70% of all vitamin E consumed in the typical US diet and has weaker antioxidant capacity than a-tocopherol. 46 The concentration of a-tocopherol in normal human plasma is 4-10 times higher than the concentration of g-tocopherol, 45 as confirmed in our study. The activity of cytochrome P 450 is considered an important regulator of plasma and tissue concentrations of g-tocopherol and large doses of atocopherol, present in vitamin E supplements, are known to deplete plasma g-tocopherol through increased degradation by cytochrome P 450. 45 We performed a retrospective analysis of vitamin or mineral supplement use by the study subjects at the time of the blood draw. Up to 30% of controls reported vitamin or mineral supplement use on a regular basis. However, owing to a very low response rate we were unable to obtain an accurate measure of vitamin or supplement use in the HSCT population. We believe this was owing to the 50% mortality rate in the HSCT group along with reluctance among survivors or family members to respond to the questionnaire. Therefore, we cannot exclude differences in vitamin and mineral supplement use as a cause for the increase in plasma g-tocopherol concentration in the HSCT subjects compared with controls.
Proinflammatory cytokines are reported to inhibit the activity of cytochrome P 450 thus reducing degradation of g-tocopherol and allowing plasma levels to increase. 47, 48 The biological implications of an elevated plasma concentration of g-tocopherol are not well understood. Recent in vitro data suggest that g-tocopherol inhibits proliferation of malignant cells by reducing cyclin D1 and cyclin E levels through a non-antioxidant mechanisms. 46 It is not clear to what extent there is synergy between g-tocopherol and other antioxidants and we were unable to show any negative correlation between the reduced plasma concentrations of GPX-3 and the elevated plasma concentrations of g-tocopherol. Data from animals suggests that gtocopherol accumulates with age possibly as a compensation for an age-associated increase in ROS production and peroxynitrite formation that has been shown to occur in vascular aging. 49 Thus, the increase in g-tocopherol that we have observed may be either a response to accumulated chemotherapy-related oxidative stress in the pre-HSCT subject or may be an attempt to compensate for the lower plasma concentration of GPX-3. Data from the physicians health study shows that higher plasma levels of gtocopherol are associated with an increased risk of myocardial infarction 50 and may be a marker for trans fat intake. 50 Therefore, the increase in g-tocopherol that we have observed may increase the risk of vascular events in those surviving HSCT.
This study has some limitations. The mean age of the control group was lower than that of the HSCT group and may have affected the results. The study was not a comprehensive analysis of all enzymatic and non-enzymatic antioxidants in subjects before HSCT. At the time of the study we did not collect data on vitamin and mineral supplement use and were unable to obtain accurate data on supplement use by subjects in both groups retrospectively. Therefore we cannot exclude an effect of supplement use on the results.
In summary, we have observed a significant reduction in the plasma concentration of GPX-3 in subjects undergoing HSCT. In addition, the concentration of g-tocopherol was significantly elevated before HSCT. Despite these changes, HSCT plasma retained the ability to quench ROS in a translational model of oxidative stress. Further studies are needed to determine if these changes contribute to an ongoing self-perpetuating chronic oxidative stress and possibly premature cellular or organ senescence in subjects undergoing HSCT.
